AAAAAA

   
Results: 1-17 |
Results: 17
Pure selective estrogen receptor modulators, new molecules having absolutecell specificity ranging from pure antiestrogenic to complete estrogen-like activities
Authors: Labrie, F Labrie, C Belanger, A Giguere, V Simard, J Merand, Y Gauthier, S Luu-The, V Candas, B Martel, C Luo, SQ
Citation: F. Labrie et al., Pure selective estrogen receptor modulators, new molecules having absolutecell specificity ranging from pure antiestrogenic to complete estrogen-like activities, ADV PROTEIN, 56, 2001, pp. 293
The Laval University screening trial results
Authors: Labrie, F Candas, B Cusan, L Gomez, JL
Citation: F. Labrie et al., The Laval University screening trial results, CURR CLIN U, 2001, pp. 255-279
Evaluation of prostatic specific antigen and digital rectal examination asscreening tests for prostate cancer
Authors: Candas, B Cusan, L Gomez, JL Diamond, P Suburu, RE Levesque, J Brousseau, G Belanger, A Labrie, F
Citation: B. Candas et al., Evaluation of prostatic specific antigen and digital rectal examination asscreening tests for prostate cancer, PROSTATE, 45(1), 2000, pp. 19-35
Androgen blockade in prostate cancer
Authors: Labrie, F Candas, B
Citation: F. Labrie et B. Candas, Androgen blockade in prostate cancer, LANCET, 356(9226), 2000, pp. 341-341
Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice
Authors: Couillard, S Labrie, C Gauthier, S Merand, Y Singh, SM Candas, B Labrie, F
Citation: S. Couillard et al., Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice, INT J CANC, 85(3), 2000, pp. 424-429
Long-term combined androgen blockade alone for localized prostate cancer
Authors: Labrie, F Cusan, L Gomez, JL Belanger, A Candas, B
Citation: F. Labrie et al., Long-term combined androgen blockade alone for localized prostate cancer, MOL UROL, 3(3), 1999, pp. 217-225
EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen inthe mammary gland and endometrium
Authors: Labrie, F Labrie, C Belanger, A Simard, J Gauthier, S Luu-The, V Merand, Y Giguere, V Candas, B Luo, SQ Martel, C Singh, SM Fournier, M Coquet, A Richard, V Charbonneau, R Charpenet, G Tremblay, A Tremblay, G Cusan, L Veilleux, R
Citation: F. Labrie et al., EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen inthe mammary gland and endometrium, J STEROID B, 69(1-6), 1999, pp. 51-84
Rationale for randomised trials of prostate cancer screening
Authors: Alexander, FE Andriole, GL Aus, G Auvinen, A Beensterboer, P Blijenberg, BG Bonardi, R Buys, S Candas, B Ciatto, S Crawford, ED Demers, R de Koning, HJ Denis, L Dijk, MA Figueiredo, F Gellman, EP Gohagan, J Hakama, M Hugosson, J Kirkels, WI Kranse, R van der Kwast, TH Lilja, H Maattanen, L Mandel, J Miller, AB Monteiro, H Nelen, V Oberman, A Paez, A Prorok, PC Reding, D Rietbergen, JWBW Rose, DB Sanchez, AB Schroder, FH da Silva, EC Simpson, N Smith, PH Stadaert, B Stenman, UH Teppo, L Turkes, A Weissfeld, JL Yokochi, L
Citation: Fe. Alexander et al., Rationale for randomised trials of prostate cancer screening, EUR J CANC, 35(2), 1999, pp. 262-271
Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial
Authors: Labrie, F Candas, B
Citation: F. Labrie et B. Candas, Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial, PROSTATE, 40(2), 1999, pp. 132-134
The Quebec study shows a 69% decrease in prostate cancer death
Authors: Labrie, F Candas, B
Citation: F. Labrie et B. Candas, The Quebec study shows a 69% decrease in prostate cancer death, PROSTATE, 40(2), 1999, pp. 137-137
Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
Authors: Labrie, F Candas, B Dupont, A Cusan, L Gomez, JL Suburu, RE Diamond, P Levesque, J Belanger, A
Citation: F. Labrie et al., Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial, PROSTATE, 38(2), 1999, pp. 83-91
Relative potency of bicalutamide (Casodex) and flutamide (Eulexin) - Reply
Authors: Labrie, F Simard, J Coquet, A Lablanc, G Candas, B
Citation: F. Labrie et al., Relative potency of bicalutamide (Casodex) and flutamide (Eulexin) - Reply, UROLOGY, 54(1), 1999, pp. 195-197
Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: Three versus six months of endocrine therapy
Authors: van der Kwast, TH Tetu, B Candas, B Gomez, JL Cusan, L Labrie, F
Citation: Th. Van Der Kwast et al., Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: Three versus six months of endocrine therapy, UROLOGY, 53(3), 1999, pp. 523-529
Bicalutamide versus flutamide in combination therapy
Authors: Labrie, F Candas, B
Citation: F. Labrie et B. Candas, Bicalutamide versus flutamide in combination therapy, UROLOGY, 53(3), 1999, pp. 662-663
Effects of the antiestrogen EM-800 (SCH 57050)and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice
Authors: Gutman, M Couillard, S Labrie, F Candas, B Labrie, C
Citation: M. Gutman et al., Effects of the antiestrogen EM-800 (SCH 57050)and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice, CANCER RES, 59(20), 1999, pp. 5176-5180
Effect of combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice
Authors: Couillard, S Gutman, M Labrie, F Candas, B Labrie, C
Citation: S. Couillard et al., Effect of combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice, CANCER RES, 59(19), 1999, pp. 4857-4863
Morphologic effects of neoadjuvant hormone therapy on prostate cancer
Authors: Tetu, B Van der Kwast, TH Fradet, Y Candas, B Gomez, JL Cusan, L Labrie, F
Citation: B. Tetu et al., Morphologic effects of neoadjuvant hormone therapy on prostate cancer, MOL UROL, 2(3), 1998, pp. 103-107
Risultati: 1-17 |